Factors associated with celecoxib and rofecoxib utilization

Annals of Pharmacotherapy

Volumn 39, Issue 4, 2005, Pages 597-602

  Rawson, Nigel S B ^a,b   Nourjah, Parivash ^c   Grosser, Stella C ^c   Graham, David J ^c  

^a Ctr for Hlth Care Plcy and Eval   (United States)

^b GLAXOSMITHKLINE   (Canada)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Celecoxib; Cyclooxygenase 2 inhibitors; Determinants of prescribing; Disease burden; Nonsteroidal antiinflammatory drugs; Rofecoxib

Indexed keywords

CELECOXIB; CORTICOSTEROID; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; OXAPROZIN; PIROXICAM; ROFECOXIB; SALSALATE; SULINDAC; TOLMETIN;

AGE DISTRIBUTION; ANALYTIC METHOD; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG CHOICE; DRUG UTILIZATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER TOXICITY; LOGISTIC REGRESSION ANALYSIS; MEDICAL SPECIALIST; NEPHROTOXICITY; PATIENT SELECTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DATABASES, FACTUAL; FEMALE; HEALTH CARE SECTOR; HUMANS; LACTONES; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PRESCRIPTIONS, DRUG; PYRAZOLES; RISK FACTORS; SULFONAMIDES; SULFONES;

EID: 15444367516     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E298     Document Type: Article

References (28)

1. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis - the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
3. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000;43:1905-15.
4. Collet JP, Boivin JF. Bias and confounding in pharmacoepidemiology. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. Chichester, England: Wiley, 2000:765-84.
5. Rawson NSB, Inman WHW. Prescription-event monitoring: recent experience with five NSAIDs. Med Toxicol 1986;1(suppl 1):79-82.
6. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
7. Solomon DH, Schneewejss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-73.
8. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. www.fda.gov/bbs/topics/news/2004/NEW01122. html (accessed 2004 Sept 30).
9. Merck announces voluntary worldwide withdrawal of Vioxx. www.merck.com/newsroom/press_releases/product/2004_0930.html (accessed 2004 Sept 30).
10. Shatin D, Rawson NSB, Stergachis A. UnitedHealth Group. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. Chichester, England: Wiley (in press).
11. Etminan M. Pharmacoepidemiology II: the nested case-control study - a novel approach in pharmacoepidemiologic research. Pharmacotherapy 2004;24:1105-9.
12. SAS OnlineDoc, version 8. Cary, NC: SAS Institute, 1999.
13. SAS Technical Support. Floating point zero divide error or floating point overflow may occur in PROC PHREG. Cary, NC: SAS Institute, 2002. http://support.sas.com/techsup/unotes/SN/007/007140.html (accessed 2004 Apr 15).
14. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
15. Singh G, Ramey DR. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. J Rheumatol 1998;25(suppl 51):8-16.
16. Cox ER, Motheral B, Frisse M, Behm A, Mager D. Prescribing COX-2s for patients new to cyclo-oxygenase inhibition therapy. Am J Manag Care 2003;9:735-42.
17. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, et al. Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481-92.
18. News release. Pfizer provides information to health care professionals about its COX-2 medicine Bextra (valdecoxib). www.pfizer.com/are/news_releases/ 2004pr/mn_2004_1015.html (accessed 2004 Oct 15).
19. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FWA, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.
20. NIH halts use of COX-2 inhibitor in large cancer prevention trial. www.nci.nih.gov/newscenter/pressreleases/APCtrialCOX2 (accessed 2005 Jan 10).
21. Pfizer statement on new information regarding cardiovascular safety of Celebrex. www.celebrex.com/cardiovascular_safety_of_celebrex_tp.asp (accessed 2005 Jan 10).
22. FDA statement on the halting of a clinical trial of the COX-2 inhibitor Celebrex. www.fda.gov/bbs/topics/news/2004/NEW01144.html (accessed 2005 Jan 10).
23. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
24. Smalley WE, Ray WA, Daugherty J, Griffin MR. Nonsteroidal anti-inflammatory drug use and colorectal cancer incidence: a population-based study. Arch Intern Med 1999;159:161-6.
25. Griffin MR, Yared A, Ray WA. Nonsteroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000;151:488-96.
26. Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med 2003;115:715-20.
27. Rahme E, Marentette MA, Kong SX, LeLorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum 2002;47:595-602.
28. Rawson NSB, D'Arcy C. Assessing the validity of diagnostic information in administrative health care utilization data: experience in Saskatchewan. Pharmacoepidemiol Drug Saf 1998;7:389-98.